Market Exclusive

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gets upgraded to Outperform by Svb Leerink with a price target of $50.00

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Today, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock received an upgrade by Svb Leerink from Market Perform to Outperform with a price target of $50.00.

There are 10 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $45.1538 per share, a potential 12.77% upside.

Some recent analyst ratings include

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 39.98 up +0.84 2.15% with 40.12 shares trading hands.

Exit mobile version